ReviewInternational journal of molecular sciences2021
Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 4 syntheses or guidelines pooled it, 164 citations in OpenAlex.
- A systematic review and meta-analysis of the prevalence and risk factors of prostate cancer in Nigeria.BMC cancer · 2025Pooled it
- BioBERT-powered synergy: advanced bibliometric and molecular insights into prostate cancer bone metastasis.Frontiers in immunology · 2025Pooled it
- Association between polyphenol subclasses and prostate cancer: a systematic review and meta-analysis of observational studies.Frontiers in nutrition · 2024Pooled it
- Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine.Prostate cancer and prostatic diseases · 2023Pooled it
- Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Trial
- 177 Lu-PSMA for prostate cancer: progress, challenges and future perspectives.Asian journal of andrology · 2026Review
- Next-generation sequencing-based characterization of BRCA1/2 variants across multiple tumor types in Vietnamese patients.BMC cancer · 2026Article
- Socioeconomic and Demographic Factors in Genetic Testing Utilization Among Advanced Prostate Cancer Patients.The Prostate · 2026Article
- Integrative multi-omics analysis identifies key ubiquitination regulators in prostate cancer.Translational oncology · 2026Article
- Polygenic risk scores for premagnetic resonance imaging risk stratification in men with clinically suspected prostate cancer.Journal of the National Cancer Institute · 2026Article
- Co-Pathogenic Role of BRCA1 and OBSCN Deletions in Chinese Familial Breast Cancer: A Case Report.The American journal of case reports · 2026Article
- 3,3'-Di-O-methylellagic Acid Isolated fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Long-Term Outcomes of Low-Dose-Rate Brachytherapy in Localized Prostate Cancer: A 17-Year Retrospective Analysis of a Single-Center Portuguese Cohort.Journal of clinical medicine · 2026Article
- In Silico and In Vitro Investigation of Apoptosis-Mediated Antiproliferative Activity of Capsaicin and Alpha-Lipoic Acid Against Prostate Cancer Cells.Current issues in molecular biology · 2026Article
- Integrative Whole-Genome and Epigenome Profiling of cfDNA in Familial Prostate Cancer: Insights from a Pilot Study.Biomedicines · 2026Article
- Unique perspectives about men's awareness of BRCA1/2 genetic testing in primary care.Scientific reports · 2026Article
- Delphi panel consensus on genetic testing for prostate cancer in Australia: Whom to test and how?Familial cancer · 2026Article
- Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?International journal of molecular sciences · 2026Review
- Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice.Journal of multidisciplinary healthcare · 2026Review
- Risk factors for cognitive dysfunction in prostate cancer patients undergoing androgen deprivation therapy: a retrospective study.American journal of translational research · 2026Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most common cause of cancer-related deaths in men. Family history of PCa, hereditary breast and ovarian cancer (HBOC) and Lynch syndromes (LS), are among the most important risk factors compared to age, race, ethnicity and environmental factors for PCa development. Hereditary prostate cancer (HPCa) has the highest heritability of any major cancer in men. The proportion of PCa attributable to hereditary factors has been estimated in the range of 5-15%. To date, the genes more consistently associated to HPCa susceptibility include mismatch repair (MMR) genes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.